John Kastelein, M.D., Ph.D. FESC

John Kastelein, M.D., Ph.D. FESC

Chief Scientific OfficeratNewAmsterdam Pharma Co· In proxies 2023–2025

Pay in FY2025+42% from the year before · NewAmsterdam Pharma Co stock +36.5% the same year

John Kastelein, M.D., Ph.D. FESC was paid $4.8M in FY2025 (Dec), up 42%. NewAmsterdam Pharma Co stock rose 36.5% that year.

Pay$100 in the stock at the end of FY22 → $322
Pay is from the Summary Compensation Table of each NewAmsterdam Pharma Co proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. NewAmsterdam Pharma CoPublic company · 3 yr
    • Chief Scientific Officer2023 – Present · 3 yrStock in role +83%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?